

ANTICOAGULANT FUSION PROTEIN ANCHORED TO CELL MEMBRANE

Publication number: JP2001523094 (T)

Publication date: 2001-11-20

Inventor(s):

Applicant(s):

Classification:

- International: A01K87/027; A61K38/00; A61P37/06; A61P7/02; C07K14/705; C07K14/73; C07K14/74; C07K14/81; C07K14/815; C07K19/00; C12N1/15; C12N1/19; C12N1/21; C12N1/509; C12N1/562; C12N1/565; C12N5/10; C12N9/04; A61K48/00; A61K87/027; A61K38/00; A61P37/06; A61P7/00; C07K14/435; C07K14/81; C07K19/00; C12N1/15; C12N1/19; C12N1/21; C12N1/509; C12N1/562; C12N1/565; C12N5/10; C12N9/04; A61K48/00; (IPC1-7); A01K87/027; A61K38/00; A61P37/06; A61P7/02; C07K14/705; C07K14/815; C07K19/00; C12N1/15; C12N1/19; C12N1/21; C12N1/509; C12N5/10

- European: C12N1/562; C12N1/565A1

Application number: JP199805452207 19980326

Priority number(s): GB1997006327 19970326; GB1997002048 19970923; WO1998GB00850 19980326

Also published as:

JP4243355 (B2)

WO9842850 (A1)

US6423316 (B1)

NZ50007 (A)


JP2008109039 (A)

more >>

Abstract not available for JP 2001523094 (T)

Abstract of corresponding document: WO 9842850 (A1)

The invention relates to the inhibition of blood coagulation, especially during organ rejection, and in particular the inhibition of delayed vascular rejection. The invention provides anticoagulant proteins which are anchored to cell membranes. The anticoagulant function is preferably provided by heparin, antithrombin, fibrin, TFP1, tick anticoagulant peptide, or a snake venom factor. These anticoagulant proteins are preferably prevented from being constitutively expressed at the cell surface. In particular, expression at the cell surface is regulated according to cell activation, for instance by targeting the protein to a suitable secretory granule. Expression of these proteins renders cells, tissues and organs less vulnerable to rejection after transplantation (e.g. after xenotransplantation).



Data supplied from the [espacenet](http://www.espacenet.com) database — Worldwide